Design Cells/iStock via Getty Images
Shares of Mustang Bio (NASDAQ:MBIO) jumped on Monday after the company said that the U.S. FDA has granted orphan drug status to its CAR T-cell therapy, MB-101, for the treatment of astrocytoma and glioblastoma, types of brain tumour.
The stock